...
首页> 外文期刊>BMC Cancer >Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4–ALK -rearranged non–small–cell lung cancer harbored coexisting EGFR mutation
【24h】

Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4–ALK -rearranged non–small–cell lung cancer harbored coexisting EGFR mutation

机译:EGFR酪氨酸激酶和ALK抑制剂对EML4–ALK重排的非小细胞肺癌具有EGFR突变的活性

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background The EML4–ALK (echinoderm microtubule-associated protein-like 4 gene and the anaplastic lymphoma kinase gene) fusion oncogene represents a novel molecular target in a small subset of non–small–cell lung cancers (NSCLCs). The EML4–ALK fusion gene occurs generally in NSCLC without mutations in epidermal growth factor receptor (EGFR) and KRAS . Case presentation We report that a case of EML4–ALK -positive NSCLC with EGFR mutation had a response of stable disease to both an EGFR tyrosine kinase inhibitor (EGFR-TKI) and ALK inhibitor. Conclusions We described the first clinical report of a patient with EML4–ALK -positive NSCLC with EGFR mutation that had a response of stable disease to both single-agent EGFR-TKI and ALK inhibitor. EML4–ALK translocation may be associated with resistance to EGFR-TKI, and EGFR signaling may contribute to resistance to ALK inhibitor in EML4–ALK -positive NSCLC.
机译:背景EML4-ALK(棘皮动物微管相关蛋白样4基因和间变性淋巴瘤激酶基因)融合癌基因代表了一小部分非小细胞肺癌(NSCLC)的新型分子靶标。 EML4-ALK融合基因通常出现在NSCLC中,而表皮生长因子受体(EGFR)和KRAS没有突变。病例介绍我们报告说,一例具有EGFR突变的EML4-ALK阳性NSCLC对EGFR酪氨酸激酶抑制剂(EGFR-TKI)和ALK抑制剂均具有稳定的疾病反应。结论我们描述了具有EGFR突变的EML4-ALK阳性NSCLC患者的第一份临床报告,该患者对单药EGFR-TKI和ALK抑制剂均具有稳定的疾病反应。 EML4-ALK阳性NSCLC患者中EML4-ALK易位可能与对EGFR-TKI的耐药有关,而EGFR信号转导可能对ALK抑制剂产生抗性。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号